Skip to main content
Top
Gepubliceerd in: Quality of Life Research 5/2023

13-11-2022 | Special Section: Methodologies for Meaningful Change

Comparison of anchor-based methods for estimating thresholds of meaningful within-patient change using simulated PROMIS PF 20a data under various joint distribution characteristic conditions

Auteurs: Shanshan Qin, Lauren Nelson, Nicole Williams, Valerie Williams, Randall Bender, Lori McLeod

Gepubliceerd in: Quality of Life Research | Uitgave 5/2023

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

To compare the performance of anchor-based methods for estimating thresholds of meaningful within-patient change (i.e., individual change) of clinical outcome assessments in conditions reflecting data characteristics of small- to medium-sized clinical trials.

Methods

Datasets were generated from the joint distributions of the PROMIS PF 20a T-score changes and a seven-point global change anchor measure. The 108 simulation conditions (1000 replications per condition) included combinations of three marginal distributions of T-score changes, three improvement percentages in the anchor measure, four levels of responsiveness correlations, and three sample sizes. Threshold estimation methods included mean change, median change, ROC curve, predictive modeling, half SD, and SEM. Relative bias, precision, accuracy, and measurement significance of the estimates were evaluated based on comparison with true thresholds and IRT-based individual reliable changes of PROMIS scores. Quantile regression models were applied to select and interpret effects of simulation conditions on estimation bias.

Results

When PROMIS T-score changes were distributed normally, the predictive modeling method performed best with 50% or more responders identified by the anchor; the mean and median methods were preferred with 30% responders. For skewed distributions, the median method and ROC method gained more advantages. Among the evaluated study conditions, the improvement percentage condition had the most obvious effects on estimation bias.

Conclusion

To establish accurate and precise thresholds, clinical researchers are recommended to prioritize study designs with at least 50% anchor-defined responders and strongly responsive target endpoints with highly reliable scoring calibration and to select optimal anchor-based methods given the data characteristics.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference U.S. Department of Health and Human Services, Food and Drug Administration. (2009). Guidance for industry: Patient-reported outcome measures: use in medical product development to support labeling claims. Retrieved November 25, 2021, from https://www.fda.gov/media/77832/download U.S. Department of Health and Human Services, Food and Drug Administration. (2009). Guidance for industry: Patient-reported outcome measures: use in medical product development to support labeling claims. Retrieved November 25, 2021, from https://​www.​fda.​gov/​media/​77832/​download
2.
go back to reference Food and Drug Administration. (2018). Patient-focused drug development guidance public workshop: methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. Guidance 3 discussion document. Retrieved November 25, 2021, from https://www.fda.gov/media/116277/download Food and Drug Administration. (2018). Patient-focused drug development guidance public workshop: methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. Guidance 3 discussion document. Retrieved November 25, 2021, from https://​www.​fda.​gov/​media/​116277/​download
3.
go back to reference Food and Drug Administration. (2019). Patient-focused drug development guidance public workshop: incorporating clinical outcome assessments into endpoints for regulatory decision making. Guidance 4 discussion document. Retrieved April 18, 2021, from https://www.fda.gov/media/132505/download Food and Drug Administration. (2019). Patient-focused drug development guidance public workshop: incorporating clinical outcome assessments into endpoints for regulatory decision making. Guidance 4 discussion document. Retrieved April 18, 2021, from https://​www.​fda.​gov/​media/​132505/​download
7.
go back to reference Coon, C. D. (2016). Telling the interpretation story: The case for strong anchors and multiple methods. Plenary presentation at the ISOQOL 23rd Annual Conference; October 19, 2016. Copenhagen, Denmark Coon, C. D. (2016). Telling the interpretation story: The case for strong anchors and multiple methods. Plenary presentation at the ISOQOL 23rd Annual Conference; October 19, 2016. Copenhagen, Denmark
18.
go back to reference Cella, D., Riley, W., Stone, A., Rothrock, N., Reeve, B., Yount, S., Amtmann, D., Bode, R., Buysse, D., Choi, S., Cook, K., Devellis, R., DeWalt, D., Fries, J. F., Gershon, R., Hahn, E. A., Lai, J. S., Pilkonis, P., Revicki, D., … PROMIS Cooperative Group. (2010). The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. Journal of Clinical Epidemiology, 63(11), 1179–1194. https://doi.org/10.1016/j.jclinepi.2010.04.011CrossRefPubMedPubMedCentral Cella, D., Riley, W., Stone, A., Rothrock, N., Reeve, B., Yount, S., Amtmann, D., Bode, R., Buysse, D., Choi, S., Cook, K., Devellis, R., DeWalt, D., Fries, J. F., Gershon, R., Hahn, E. A., Lai, J. S., Pilkonis, P., Revicki, D., … PROMIS Cooperative Group. (2010). The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. Journal of Clinical Epidemiology, 63(11), 1179–1194. https://​doi.​org/​10.​1016/​j.​jclinepi.​2010.​04.​011CrossRefPubMedPubMedCentral
20.
go back to reference Wicklin, R. (2013). Simulating Data with SAS®. SAS Institute Inc. Wicklin, R. (2013). Simulating Data with SAS®. SAS Institute Inc.
21.
go back to reference Coles, T. M., Chen, W., Nelson, L. M., Williams, V. S., Williams, N. J., & McLeod L. D. Current sample size practices in the psychometric evaluation of patient-reported outcome measures for use in clinical trials. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 8-12, 2014. Amsterdam Coles, T. M., Chen, W., Nelson, L. M., Williams, V. S., Williams, N. J., & McLeod L. D. Current sample size practices in the psychometric evaluation of patient-reported outcome measures for use in clinical trials. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 8-12, 2014. Amsterdam
22.
go back to reference SAS Institute Inc. (2012). SAS proprietary software, version 9.4. SAS Institute Inc. SAS Institute Inc. (2012). SAS proprietary software, version 9.4. SAS Institute Inc.
25.
go back to reference Musoro, J. Z., Bottomley, A., Coens, C., Eggermont, A. M., King, M. T., Cocks, K., Sprangers, M. A., Groenvold, M., Velikova, G., Flechtner, H. H., Brandberg, Y., EORTC Melanoma Group and EORTC Quality of Life Group. (2018). Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma. European Journal of Cancer, 104, 169–181. https://doi.org/10.1016/j.ejca.2018.09.005CrossRefPubMed Musoro, J. Z., Bottomley, A., Coens, C., Eggermont, A. M., King, M. T., Cocks, K., Sprangers, M. A., Groenvold, M., Velikova, G., Flechtner, H. H., Brandberg, Y., EORTC Melanoma Group and EORTC Quality of Life Group. (2018). Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma. European Journal of Cancer, 104, 169–181. https://​doi.​org/​10.​1016/​j.​ejca.​2018.​09.​005CrossRefPubMed
29.
go back to reference Mehta, L., McNeill, M., Hobart, J., Wyrwich, K. W., Poon, J. L., Auguste, P., Zhong, J., & Elkins, J. (2015). Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results. Multiple Sclerosis Journal—Experimental, Translational, and Clinical, 1, 2055217315596993. https://doi.org/10.1177/2055217315596993CrossRefPubMed Mehta, L., McNeill, M., Hobart, J., Wyrwich, K. W., Poon, J. L., Auguste, P., Zhong, J., & Elkins, J. (2015). Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results. Multiple Sclerosis Journal—Experimental, Translational, and Clinical, 1, 2055217315596993. https://​doi.​org/​10.​1177/​2055217315596993​CrossRefPubMed
Metagegevens
Titel
Comparison of anchor-based methods for estimating thresholds of meaningful within-patient change using simulated PROMIS PF 20a data under various joint distribution characteristic conditions
Auteurs
Shanshan Qin
Lauren Nelson
Nicole Williams
Valerie Williams
Randall Bender
Lori McLeod
Publicatiedatum
13-11-2022
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 5/2023
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-022-03285-x

Andere artikelen Uitgave 5/2023

Quality of Life Research 5/2023 Naar de uitgave

Special Section: Methodologies for Meaningful Change

Measuring individual true change with PROMIS using IRT-based plausible values